Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab

BACKGROUND: Preliminary evidence indicates that early tumor shrinkage (ETS) following immune checkpoint inhibitor (ICI) initiation may be associated with survival outcomes in patients with advanced melanoma. ETS has not been explored as a biomarker of survival outcomes or patient-reported outcomes i...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Immunother Cancer
Päätekijät: Hopkins, Ashley M, Kichenadasse, Ganessan, Karapetis, Chris S, Rowland, Andrew, Sorich, Michael J
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMJ Publishing Group 2020
Aiheet:
Immunotherapy Biomarkers
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7279663/
https://ncbi.nlm.nih.gov/pubmed/32503948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000500
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia